InvestorsHub Logo
Followers 12
Posts 788
Boards Moderated 0
Alias Born 09/26/2018

Re: sstyles post# 349514

Thursday, 08/05/2021 12:43:48 PM

Thursday, August 05, 2021 12:43:48 PM

Post# of 426264
Agreed, but that is a different set of facts. Look, the GSK/Teva case is a nice incremental move and an important shift, but certainly doesn't 100% seal things up.

Does it shift the risk/reward for generics with respect to Vascepa, which is expensive and difficult to mfg? I certainly think yes.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News